Rain Therapeutics Performance
| RAINDelisted Stock | USD 1.41 0.01 0.70% |
The company holds a Beta of 0.73, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Rain Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Rain Therapeutics is expected to be smaller as well. Rain Therapeutics right now holds a risk of 0.0%. Please check Rain Therapeutics potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Rain Therapeutics will be following its historical price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Rain Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy forward indicators, Rain Therapeutics is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 39.8 M | |
| Free Cash Flow | -68.4 M |
Rain |
Rain Therapeutics Relative Risk vs. Return Landscape
If you would invest 141.00 in Rain Therapeutics on August 27, 2024 and sell it today you would earn a total of 0.00 from holding Rain Therapeutics or generate 0.0% return on investment over 90 days. Rain Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Rain, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Rain Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Rain Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Rain Therapeutics, and traders can use it to determine the average amount a Rain Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| RAIN |
Based on monthly moving average Rain Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Rain Therapeutics by adding Rain Therapeutics to a well-diversified portfolio.
Rain Therapeutics Fundamentals Growth
Rain Stock prices reflect investors' perceptions of the future prospects and financial health of Rain Therapeutics, and Rain Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Rain Stock performance.
| Return On Equity | -0.97 | |||
| Return On Asset | -0.52 | |||
| Current Valuation | (32.85 M) | |||
| Shares Outstanding | 27.58 M | |||
| Price To Book | 0.65 X | |||
| EBITDA | (73.56 M) | |||
| Cash And Equivalents | 90.73 M | |||
| Cash Per Share | 3.41 X | |||
| Total Debt | 277 K | |||
| Debt To Equity | 0 % | |||
| Book Value Per Share | 1.86 X | |||
| Cash Flow From Operations | (65.76 M) | |||
| Earnings Per Share | (2.07) X | |||
| Total Asset | 135.18 M | |||
| Retained Earnings | (165.69 M) | |||
About Rain Therapeutics Performance
By examining Rain Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Rain Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Rain Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California. Rain Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 44 people.Things to note about Rain Therapeutics performance evaluation
Checking the ongoing alerts about Rain Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Rain Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Rain Therapeutics is not yet fully synchronised with the market data | |
| Rain Therapeutics may become a speculative penny stock | |
| Rain Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (72.26 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Rain Therapeutics currently holds about 90.73 M in cash with (65.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.41, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 68.0% of the company shares are owned by institutional investors |
- Analyzing Rain Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Rain Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Rain Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Rain Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Rain Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Rain Therapeutics' stock. These opinions can provide insight into Rain Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Other Consideration for investing in Rain Stock
If you are still planning to invest in Rain Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rain Therapeutics' history and understand the potential risks before investing.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |